{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:03:18Z","timestamp":1781013798984,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Advanced MRI techniques may provide non-invasive insight into the molecular heterogeneity of glioblastoma. Amide proton transfer-weighted (APTw) chemical exchange saturation transfer (CEST) MRI reflects endogenous protein and peptide content, but its clinical and molecular correlates in therapy-naive glioblastoma, IDH-wildtype, remain incompletely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective single-center study included 53 adult patients with therapy-naive glioblastoma, IDH-wildtype, who underwent preoperative APTw MRI. Median time between imaging and tissue sampling was two days. Median and 90th percentile (p90) APTw signal intensities were extracted from contrast-enhancing (T1-CE) tumor regions and FLAIR-hyperintense regions using automated deep learning-based segmentation with manual quality control. Histological and molecular analyses included\n                      <jats:italic>MGMT<\/jats:italic>\n                      promoter methylation, Ki-67 index, and DNA methylation-based subclassification. Associations were assessed using non-parametric tests, multivariable linear regression, and Cox regression analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      APTw signal intensity was significantly higher in T1-CE tumor regions than in FLAIR-hyperintense regions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Within the T1-CE region, higher APTw signal intensity was modestly associated with younger age. Glioblastomas of the mesenchymal methylation subtype demonstrated significantly higher median and p90 APTw signal intensity compared with RTK1 and RTK2 subtypes, independent of\n                      <jats:italic>MGMT<\/jats:italic>\n                      status and Ki-67 index. APTw signal intensity was not independently associated with PFS or OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>APTw CEST MRI reflects molecular heterogeneity in therapy-naive IDH-wildtype glioblastoma, with potentially increased signal intensity in the mesenchymal subtype. These findings support its possible role as a complementary imaging biomarker for non-invasive molecular characterization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05616-1","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:31:37Z","timestamp":1779197497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypes"],"prefix":"10.1007","volume":"178","author":[{"given":"Thomas","family":"Zeyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scheuble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea L.","family":"Friker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Regnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Effland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Paech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"5616_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf177","author":"PY Wen","year":"2025","unstructured":"Wen PY, Weller M, Lee EQ et al (2025) Glioblastoma in adults: a Society for Neuro-Oncology and European Society of Neuro-Oncology consensus review on current management and future directions. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf177","journal-title":"Neuro Oncol"},{"issue":"8","key":"5616_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"33","key":"5616_CR3","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY van den Wen","year":"2023","unstructured":"van den Wen PY, Youssef G et al (2023) RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41(33):5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"issue":"7","key":"5616_CR4","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1016\/j.acra.2025.04.008","volume":"32","author":"Y Chen","year":"2025","unstructured":"Chen Y, Guo W, Li Y et al (2025) Differentiation of glioblastoma and solitary brain metastasis using brain-tumor interface radiomics features based on MR images: a multicenter study. Acad Radiol 32(7):4164\u20134176. https:\/\/doi.org\/10.1016\/j.acra.2025.04.008","journal-title":"Acad Radiol"},{"key":"5616_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12880-023-01183-3","volume":"24","author":"SJ M\u00fcller","year":"2024","unstructured":"M\u00fcller SJ, Khadhraoui E, Ernst M et al (2024) Differentiation of multiple brain metastases and glioblastoma with multiple foci using MRI criteria. BMC Med Imaging 24:3. https:\/\/doi.org\/10.1186\/s12880-023-01183-3","journal-title":"BMC Med Imaging"},{"issue":"2","key":"5616_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0044-1787051","volume":"19","author":"P Chuthip","year":"2024","unstructured":"Chuthip P, Sitthinamsuwan B, Witthiwej T et al (2024) Predictors for the differentiation between glioblastoma, primary central nervous system lymphoma, and metastasis in patients with a solitary enhancing intracranial mass. Asian J Neurosurg 19(2):186\u2013201. https:\/\/doi.org\/10.1055\/s-0044-1787051","journal-title":"Asian J Neurosurg"},{"issue":"11","key":"5616_CR7","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.21037\/tcr-22-1390","volume":"11","author":"Y Teng","year":"2022","unstructured":"Teng Y, Chen C, Zhang Y, Xu J (2022) The feasibility of MRI texture analysis in distinguishing glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma. Transl Cancer Res 11(11):4079\u20134088. https:\/\/doi.org\/10.21037\/tcr-22-1390","journal-title":"Transl Cancer Res"},{"issue":"1","key":"5616_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12880-025-02080-7","volume":"25","author":"L Meng","year":"2025","unstructured":"Meng L, Wu X, Su K, Zhong H (2025) Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study. BMC Med Imaging 25(1):524. https:\/\/doi.org\/10.1186\/s12880-025-02080-7","journal-title":"BMC Med Imaging"},{"issue":"6","key":"5616_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/jmri.28662","volume":"57","author":"L Hirschler","year":"2023","unstructured":"Hirschler L, Sollmann N, Schmitz-Abecassis B et al (2023) Advanced MR techniques for preoperative glioma characterization: part 1. J Magn Reson Imaging 57(6):1655\u20131675. https:\/\/doi.org\/10.1002\/jmri.28662","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"5616_CR10","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/jmri.28663","volume":"57","author":"G Hangel","year":"2023","unstructured":"Hangel G, Schmitz-Abecassis B, Sollmann N et al (2023) Advanced MR techniques for preoperative glioma characterization: part 2. J Magn Reson Imaging 57(6):1676\u20131695. https:\/\/doi.org\/10.1002\/jmri.28663","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"5616_CR11","doi-asserted-by":"publisher","first-page":"e4731","DOI":"10.1002\/nbm.4731","volume":"36","author":"S Jiang","year":"2023","unstructured":"Jiang S, Wen Z, Ahn SS et al (2023) Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas. NMR Biomed 36(6):e4731. https:\/\/doi.org\/10.1002\/nbm.4731","journal-title":"NMR Biomed"},{"issue":"12","key":"5616_CR12","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/neuonc\/noy073","volume":"20","author":"D Paech","year":"2018","unstructured":"Paech D, Windschuh J, Oberhollenzer J et al (2018) Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol 20(12):1661\u20131671. https:\/\/doi.org\/10.1093\/neuonc\/noy073","journal-title":"Neuro Oncol"},{"issue":"3","key":"5616_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/mrm.26820","volume":"78","author":"S Jiang","year":"2017","unstructured":"Jiang S, Zou T, Eberhart CG et al (2017) Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted MRI. Magn Reson Med 78(3):1100\u20131109. https:\/\/doi.org\/10.1002\/mrm.26820","journal-title":"Magn Reson Med"},{"issue":"3","key":"5616_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/neuonc\/not158","volume":"16","author":"O Togao","year":"2014","unstructured":"Togao O, Yoshiura T, Keupp J et al (2014) Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol 16(3):441\u2013448. https:\/\/doi.org\/10.1093\/neuonc\/not158","journal-title":"Neuro Oncol"},{"issue":"6","key":"5616_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/tomography11060064","volume":"11","author":"F Durmo","year":"2025","unstructured":"Durmo F, L\u00e4tt J, Rydelius A et al (2025) Role of amide proton transfer weighted MRI in predicting MGMT promoter methylation status, p53 status, Ki-67 index, IDH status, and ATRX expression in WHO grade 4 glioma. Tomography 11(6):64. https:\/\/doi.org\/10.3390\/tomography11060064","journal-title":"Tomography"},{"issue":"5","key":"5616_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00330-017-5182-4","volume":"28","author":"S Jiang","year":"2018","unstructured":"Jiang S, Rui Q, Wang Y et al (2018) Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. Eur Radiol 28(5):2115\u20132123. https:\/\/doi.org\/10.1007\/s00330-017-5182-4","journal-title":"Eur Radiol"},{"issue":"7697","key":"5616_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555(7697):469\u2013474. https:\/\/doi.org\/10.1038\/nature26000","journal-title":"Nature"},{"key":"5616_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.11.002","author":"M Sill","year":"2025","unstructured":"Sill M, Schrimpf D, Patel A et al (2025) Advancing CNS tumor diagnostics with expanded DNA methylation-based classification. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2025.11.002","journal-title":"Cancer Cell"},{"key":"5616_CR19","doi-asserted-by":"publisher","first-page":"1720458","DOI":"10.3389\/fonc.2025.1720458","volume":"15","author":"S Al Sharie","year":"2025","unstructured":"Al Sharie S, Sawaftah K, Qasim H, Al-Hussaini M (2025) Methylation profiling in neuropathological tumors diagnosis: a comprehensive review. Front Oncol 15:1720458. https:\/\/doi.org\/10.3389\/fonc.2025.1720458","journal-title":"Front Oncol"},{"issue":"2","key":"5616_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/neuonc\/noac177","volume":"25","author":"R Drexler","year":"2023","unstructured":"Drexler R, Sch\u00fcller U, Eckhardt A et al (2023) DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro Oncol 25(2):315\u2013325. https:\/\/doi.org\/10.1093\/neuonc\/noac177","journal-title":"Neuro Oncol"},{"issue":"2","key":"5616_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/mrm.29241","volume":"88","author":"J Zhou","year":"2022","unstructured":"Zhou J, Zaiss M, Knutsson L et al (2022) Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: application to brain tumors. Magn Reson Med 88(2):546\u2013574. https:\/\/doi.org\/10.1002\/mrm.29241","journal-title":"Magn Reson Med"},{"key":"5616_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf261","author":"T Zeyen","year":"2025","unstructured":"Zeyen T, Krause I, Decker A et al (2025) Amide proton transfer-weighted CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf261","journal-title":"Neuro Oncol"},{"issue":"3","key":"5616_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2353\/jmoldx.2007.060167","volume":"9","author":"T Mikeska","year":"2007","unstructured":"Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9(3):368\u2013381. https:\/\/doi.org\/10.2353\/jmoldx.2007.060167","journal-title":"J Mol Diagn"},{"key":"5616_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000001145","author":"K Karimian-Jazi","year":"2024","unstructured":"Karimian-Jazi K, Enbergs N, Golubtsov E et al (2024) Differentiating glioma recurrence and pseudoprogression by APTw CEST MRI. Invest Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000001145","journal-title":"Invest Radiol"},{"issue":"4","key":"5616_CR25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/mrm.21712","volume":"60","author":"J Zhou","year":"2008","unstructured":"Zhou J, Blakeley JO, Hua J et al (2008) Practical data acquisition method for human brain tumor amide proton transfer imaging. Magn Reson Med 60(4):842\u2013849. https:\/\/doi.org\/10.1002\/mrm.21712","journal-title":"Magn Reson Med"},{"issue":"2","key":"5616_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jmri.26645","volume":"50","author":"J Zhou","year":"2019","unstructured":"Zhou J, Heo HY, Knutsson L, van Zijl PCM, Jiang S (2019) APT-weighted MRI: Techniques, current neuro applications, and challenging issues. J Magn Reson Imaging 50(2):347\u2013364. https:\/\/doi.org\/10.1002\/jmri.26645","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"5616_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/mrm.20048","volume":"51","author":"J Zhou","year":"2004","unstructured":"Zhou J, Wilson DA, Sun PZ, Klaus JA, Van Zijl PC (2004) Quantitative description of proton exchange processes between water and endogenous and exogenous agents for WEX, CEST, and APT experiments. Magn Reson Med 51(5):945\u2013952. https:\/\/doi.org\/10.1002\/mrm.20048","journal-title":"Magn Reson Med"},{"issue":"2","key":"5616_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/mrm.26131","volume":"77","author":"DH Lee","year":"2017","unstructured":"Lee DH, Heo HY, Zhang K et al (2017) Quantitative assessment of the effects of water proton concentration and water T1 changes on amide proton transfer (APT) and nuclear overhauser enhancement (NOE) MRI: The origin of the APT imaging signal in brain tumor. Magn Reson Med 77(2):855\u2013863. https:\/\/doi.org\/10.1002\/mrm.26131","journal-title":"Magn Reson Med"},{"issue":"1","key":"5616_CR29","doi-asserted-by":"publisher","first-page":"16377","DOI":"10.1038\/s41598-023-43235-2","volume":"13","author":"A Rajendran","year":"2023","unstructured":"Rajendran A, Natesan C, Jawahar P et al (2023) Amide proton transfer imaging-arterial spin labeling mismatch: a new imaging biomarker for pilocytic astrocytoma. Sci Rep 13(1):16377. https:\/\/doi.org\/10.1038\/s41598-023-43235-2. Published 2023 Sep 29","journal-title":"Sci Rep"},{"issue":"11","key":"5616_CR30","doi-asserted-by":"publisher","first-page":"e1655360","DOI":"10.1080\/2162402X.2019.1655360","volume":"8","author":"I Kaffes","year":"2019","unstructured":"Kaffes I, Szulzewsky F, Chen Z et al (2019) Human mesenchymal glioblastomas are characterized by an increased immune cell presence compared to proneural and classical tumors. Oncoimmunology 8(11):e1655360. https:\/\/doi.org\/10.1080\/2162402X.2019.1655360","journal-title":"Oncoimmunology"},{"issue":"2","key":"5616_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.gendis.2023.05.025","volume":"11","author":"Y Lai","year":"2023","unstructured":"Lai Y, Lu X, Liao Y et al (2023) Crosstalk between glioblastoma and tumor microenvironment drives proneural-mesenchymal transition through ligand-receptor interactions. Genes Dis 11(2):874\u2013889. https:\/\/doi.org\/10.1016\/j.gendis.2023.05.025","journal-title":"Genes Dis"},{"issue":"4","key":"5616_CR32","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/mrm.29746","volume":"90","author":"F Kroh","year":"2023","unstructured":"Kroh F, von Knebel Doeberitz N, Breitling J et al (2023) Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. Magn Reson Med 90(4):1569\u20131581. https:\/\/doi.org\/10.1002\/mrm.29746","journal-title":"Magn Reson Med"},{"key":"5616_CR33","doi-asserted-by":"publisher","first-page":"109694","DOI":"10.1016\/j.radonc.2023.109694","volume":"184","author":"N von Knebel Doeberitz","year":"2023","unstructured":"von Knebel Doeberitz N, Kroh F, Breitling J et al (2023) CEST imaging of the APT and ssMT predict overall survival of patients with glioma at first follow-up after radiotherapy at 3T. Radiother Oncol 184:109694. https:\/\/doi.org\/10.1016\/j.radonc.2023.109694","journal-title":"Radiother Oncol"},{"issue":"9","key":"5616_CR34","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1007\/s00330-019-06066-2","volume":"29","author":"D Paech","year":"2019","unstructured":"Paech D, Dreher C, Regnery S et al (2019) Relaxation-compensated amide proton transfer MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol 29(9):4957\u20134967. https:\/\/doi.org\/10.1007\/s00330-019-06066-2","journal-title":"Eur Radiol"},{"issue":"2","key":"5616_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/neuonc\/noaa247","volume":"23","author":"J Dejaegher","year":"2021","unstructured":"Dejaegher J, Solie L, Hunin Z et al (2021) DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol 23(2):240\u2013250. https:\/\/doi.org\/10.1093\/neuonc\/noaa247","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05616-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05616-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:40:20Z","timestamp":1781012420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05616-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5616"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05616-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Helsinki declaration and approved by the local authorities (Ethics Committee of the University Bonn, number: 2024-315-BO). Due to the retrospective nature of the study and the use of anonymized clinical data, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"DP is a co-founder of relios.vision GmbH and reports speakers honoraria from Siemens Healthineers and advisory board honoraria from Guerbet, all unrelated to this work. UH reports speakers and advisory board honoraria from Medac, and consulting fees from Medac, OncomagnetX and Servier, all unrelated to this work. AE is a co-founder of relios.vision GmbH, unrelated to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}